Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen® and Oragens®.Alferon N Injection® is the company's registered trademark for its injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection. Alferon N Injection® (interferon alfa-n3 human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Alferon LDO® (Low Dose Oral) is a new experimental drug delivery platform for the Company’s highly purified, natural source alpha interferon.

Palatin Technologies, Inc. company was founded in 1986 and is based in Cranbury, New Jersey. Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of peptide, peptide mimetic, and small molecule agonist compounds with a focus on melanocortin (MC) and natriuretic peptide receptor systems in the United States. The company's products under development include PL-3994, a peptide mimetic natriuretic peptide receptor A agonist for the treatment of heart failure; Bremelanotide, a peptide melanocortin receptor agonist for the treatment of sexual dysfunction, targeting female sexual dysfunction and erectile dysfunction in patients non-responsive to current therapies; and PL-6983, a peptide melanocortin receptor agonist for the treatment of female sexual dysfunction. Its products in development also comprise melanocortin receptor-based compounds for treatment of obesity, diabetes, and related metabolic syndrome; and NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection. Palatin Technologies, Inc. has a licensing and research collaboration agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome.

Talecris Biotherapeutics Holdings Corp., a biotherapeutic and biopharmaceutical company, engages in the production and marketing of plasma-derived protein therapies worldwide. It develops, produces, markets, and distributes therapies for the people suffering from chronic and acute, immune deficiency disorders, alpha-1 antitrypsin deficiency, infectious diseases, hemophilia, and severe burns. The company's products include Gamunex, an intravenous immune globulin (IGIV) for the treatment of primary immune deficiency and autoimmune diseases; and Prolastin, an alpha-1 proteinase inhibitor (A1PI) for the treatment of alpha-1 antitrypsin deficiency-related emphysema. It also offers Hypermunes, which are antibody preparations for hepatitis, rabies, tetanus, and treatment of Rh negative women pregnant with Rh positive children; and albumin under various brand names, including Plasbumin albumin and Plasmanate plasma protein factor. Talecris Biotherapeutics Holdings Corp. is headquartered in Research Triangle Park, North Carolina.

IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

Phenomix hopes to create a pharmaceutical phenomenon by investigating and discovering new treatments for immune system ailments and metabolic diseases. The drug development company's lead product candidate dutogliptin is an oral-dose treatment aiming to stabilize glucose levels in patients with Type 2 diabetes. Other pipeline candidates target infectious and autoimmune diseases, including hepatitis C and certain types of cancer. The biotechnology firm's drug candidates focus on inhibiting complex proteins (enzymes) that promote disease within the body. The company is owned by a number of private investors.

NeuroNova wants to recharge neurons. The biopharmaceutical company is engaged in the research and development of therapies to help regenerate central nervous system cells in patients with Alzheimer's disease, Parkinson's disease, and other disorders. Its research focuses on developing drugs that will stimulate endogenous stem and progenitor cells to restore damaged areas of the brain. The company has two drug candidates nearing clinical development in addition to other compounds in the discovery and pre-clinical phases. NeuroNova was founded in 1998 and is financed by Swedish venture capital companies HealthCap, Scandinavian Life Science Venture, and Investor Growth Capital.

Wockhardt works hard in the pharmaceutical world. The research and pharmaceutical manufacturing firm employs more than 500 scientists who focus on recombinant biopharmaceuticals, generics, and new drug discovery. Wockhardt's products include injectables, tablets, liquids, and topicals (creams and ointments) that it manufactures to sell itself and for AstraZeneca, Sanofi-Aventis, Cell Therapeutics, Schering-Plough, and other major drug companies. It operates 15 manufacturing plants in India, the UK, Ireland, France, and the US, and has filed more than 250 patents for biotechnology products. The company is a subsidiary of Khorakiwala Holdings and Investments.

Teikoku Pharma USA is a wholly-owned subsidiary of Teikoku Seiyaku Inc., a specialty pharmaceutical company that develops, and manufactures enhanced pharmaceutical products based on its transdermal drug delivery technologies. Teikoku focuses its efforts in two therapeutic areas; Pain and CNS. By applying our transdermal technologies to existing actives or co-developing new formulations, Teikoku helps pharmaceutical companies extend patent protections, diversify product lines, provide better delivery mechanisms, and promote brand loyalty. Teikoku charts new territory in prescription, OTC, and medical device markets around the world, transforming ideas into ideally delivered products that carry a competitive edge in quality and innovation.

ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts. ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l.

Advion develops, manufactures and globally supports mass spectrometers, novel sample introduction and assay solutions, chip- based ion sources, chromatography systems, microfluidic flow chemistry systems and consumables for life science and related industries. We seek to enhance analysis performance and workflows. Using our deep scientific and engineering knowledge of mass spectrometry and microfludics, we leverage our passionate employees’ commitment to create quality, flexible and fit-for- purpose solutions.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.